Prognosis-oriented molecular subtypes of retroperitoneal liposarcoma

Mengmeng Xiao; Da Qin; Xiangji Li; Fanqin Bu; Shixiang Ma; Xiaobing Chen; Yu Zhao; Chenghua Luo; Li Min

doi:10.1002/ctm2.70050

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (10) : e70050 DOI: 10.1002/ctm2.70050

LETTER TO THE JOURNAL

Prognosis-oriented molecular subtypes of retroperitoneal liposarcoma

Author information +

History +

PDF

Cite this article

Download citation ▾

Mengmeng Xiao, Da Qin, Xiangji Li, Fanqin Bu, Shixiang Ma, Xiaobing Chen, Yu Zhao, Chenghua Luo, Li Min. Prognosis-oriented molecular subtypes of retroperitoneal liposarcoma. Clinical and Translational Medicine, 2024, 14(10): e70050 DOI:10.1002/ctm2.70050

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Inanir S, Kesim S, Ergelen R, et al. 68Ga-PSMA PET/CT in giant retroperitoneal liposarcoma. Clin Nucl Med. 2019; 44(11): e612-e613.

[2]	Meng J, Lu X, Jin C, et al. Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer. Clin Transl Med. 2021; 11(12): e655.

[3]	de Leval L, Alizadeh AA, Bergsagel PL, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022; 140(21): 2193-2227.

[4]	Xiao M, Li X, Bu F, et al. Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study. MedRxiv. 24311657 [Peer review of eLife]. August 09, 2024 [cited 2024 Sep 14].

[5]	Sinha SR, Haileselassie Y, Nguyen LP, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe. 2020; 27(4): 659-670.e5.

[6]	Kumari A, Pal Pathak D, Asthana S. Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of lipid metabolism. Int J Biol Sci. 2020; 16(13): 2308-2322.

[7]	Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut. 2016; 65(3): 487-501.

[8]	O’Donnell JS, Massi D, Teng MWL, et al. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. 2018; 48: 91-103.

[9]	Ye H, Wang WG, Cao J, et al. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma. Mol Med Rep. 2017; 16(5): 7784-7790.

[10]	Tarocchi M, Hannivoort R, Hoshida Y, et al. Carcinogen-induced hepatic tumors in KLF6± mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology. 2011; 54(2): 522-531.

[11]	Dechat T, Pfleghaar K, Sengupta K, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008; 22(7): 832-853.

[12]	Zhao CC, Chen J, Zhang LY, et al. Lamin B2 promotes the progression of triple negative breast cancer via mediating cell proliferation and apoptosis. Biosci Rep. 2021; 41(1): BSR20203874.

[13]	Ji J, Li H, Chen J, et al. Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycleassociated protein 3. Int J Mol Med. 2022; 50(3): 111.

[14]	Dong CH, Jiang T, Yin H, et al. LMNB2 promotes the progression of colorectal cancer by silencing p21 expression. Cell Death Dis. 2021; 12(4): 331.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.